05 FDA decisions to watch in the third quarter of 2026
Summary:
The second quarter of 2026 marked a turning point for the Food and Drug Administration. Follow BiopharmaDive’s insight of the top 05 important decisions of the FDA under new leadership
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Summary:
Novartis announced their next spending of $1.1 billion upfront to buy Myricx Bio, which has an antibody-drug conjugate payload platform that could offer an edge over current approaches.
Beyond Boston: Unlikely cities stake biotech claims
Summary:
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
China boosts prestigious grants for young scientists — will it ease competition?
Summary:
The National Natural Science Foundation of China says it will fund an extra 12,000 projects from this year.
Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms
Summary:
Merck stopped the study after the small molecule MK-1167 “did not meet the necessary efficacy criteria to warrant further investigation.”
